Archive - June 2013

Tuesday, June 4, 2013 - 11:59am

A Phase I clinical trial, funded by the American Cancer Society and launched through Roswell Park Cancer Institute's Center for Immunotherapy, is testing the safety of a cancer vaccine in humans. This vaccine, known as SurVaxM, is designed to stimulate the body’s immune system to attack tumor cells.